A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumours
The purpose of the study is to determine safety, tolerability, pharmacokinetics and
pharmacodynamics of BMS-986205 when combined with Nivolumab [an anti-Programmed cell
Death-1(anti-PD1) antibody] in patients with advanced cancers.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society